LU91271I2 - Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI) - Google Patents

Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)

Info

Publication number
LU91271I2
LU91271I2 LU91271C LU91271C LU91271I2 LU 91271 I2 LU91271 I2 LU 91271I2 LU 91271 C LU91271 C LU 91271C LU 91271 C LU91271 C LU 91271C LU 91271 I2 LU91271 I2 LU 91271I2
Authority
LU
Luxembourg
Prior art keywords
tysabri
natalizumab
pharmaceutically acceptable
acceptable derivatives
treatment
Prior art date
Application number
LU91271C
Other languages
English (en)
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of LU91271I2 publication Critical patent/LU91271I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU91271C 1994-01-25 2006-08-02 Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI) LU91271I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18626994A 1994-01-25 1994-01-25
PCT/US1995/001219 WO1995019790A1 (fr) 1994-01-25 1995-01-25 Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4

Publications (1)

Publication Number Publication Date
LU91271I2 true LU91271I2 (fr) 2006-10-02

Family

ID=22684288

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91271C LU91271I2 (fr) 1994-01-25 2006-08-02 Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)

Country Status (21)

Country Link
EP (2) EP1759709B1 (fr)
JP (5) JP4115517B2 (fr)
KR (1) KR100367948B1 (fr)
CN (1) CN1211123C (fr)
AT (1) ATE333895T1 (fr)
AU (1) AU703152B2 (fr)
CA (1) CA2182013C (fr)
DE (2) DE69535133T2 (fr)
DK (2) DK0804237T3 (fr)
ES (2) ES2270425T3 (fr)
FI (1) FI117509B (fr)
FR (1) FR06C0024I2 (fr)
HU (1) HU220799B1 (fr)
LU (1) LU91271I2 (fr)
MX (1) MX9602971A (fr)
NL (1) NL300238I2 (fr)
NO (3) NO319867B1 (fr)
NZ (1) NZ279730A (fr)
PL (1) PL181827B1 (fr)
PT (1) PT804237E (fr)
WO (1) WO1995019790A1 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
CA2153692C (fr) 1993-01-12 2011-11-08 Roy R. Lobb Molecules anticorps anti-vla4 recombinantes
ES2114183T5 (es) * 1993-02-09 2006-06-16 Biogen Idec Ma, Inc. Anticuerpo para el tratamiento de la diabetes dependiente de la insulina.
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
AU7348798A (en) * 1997-05-09 1998-12-08 John P. Robarts Research Institute, The Method for dislodging infiltrated leukocytes from a tissue
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
KR100628818B1 (ko) * 1998-09-14 2006-09-27 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 인테그린 길항제를 사용하여 다발성 골수종 및 골수종에의한 골흡수를 치료하는 방법
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
PT1173201E (pt) * 1999-04-22 2005-08-31 Biogen Idec Inc Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
DK2314315T3 (en) 1999-06-01 2015-02-02 Biogen Idec Inc Blocking monoclonal antibody to the human alpha1-I domain of VLA-1 and their use for the treatment of inflammatory diseases
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AU783110B2 (en) * 1999-12-16 2005-09-22 Biogen Ma Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
MXPA03009390A (es) 2001-04-13 2004-01-29 Biogen Inc Anticuerpos para integrina vla-1.
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
AR038605A1 (es) 2002-02-25 2005-01-19 Elan Pharm Inc Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento
EP2270049A3 (fr) * 2002-04-12 2011-03-09 Medimmune, Inc. Anticorps anti-interleukine-9 recombinants
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
JP4494977B2 (ja) * 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
KR20110098980A (ko) 2003-12-22 2011-09-02 아지노모토 가부시키가이샤 신규한 페닐알라닌 유도체
WO2006055871A2 (fr) * 2004-11-19 2006-05-26 Biogen Idec Ma Inc. Traitement de la sclerose en plaques
AU2006316629A1 (en) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with alpha 4 beta 7 integrin
EP2839843B1 (fr) 2006-05-25 2018-06-20 Biogen MA Inc. Antagoniste de VLA-1 pour une utilisation dans le traitement d'un accident vasculaire cérébral
US20100150915A1 (en) 2007-02-20 2010-06-17 Stewart Edward J Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
ES2707815T3 (es) * 2007-06-14 2019-04-05 Biogen Ma Inc Formulaciones de anticuerpo natalizumab
KR101449521B1 (ko) 2007-12-13 2014-10-13 가부시끼가이샤 도꾸야마 포토크로믹 경화성 조성물 및 경화체
EA022201B1 (ru) 2008-04-11 2015-11-30 Мерримак Фармасьютикалз, Инк. Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение
EP2408816B1 (fr) 2009-03-20 2019-09-04 Amgen Inc. Anticorps antagoniste spécifique d'un hétérodimère alpha-4-bêta-7
EP2467159A1 (fr) 2009-08-20 2012-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Vla-4 en tant que biomarqueur pour le pronostic et le ciblage pour thérapie dans la dystrophie musculaire de duchenne
HUE050858T2 (hu) 2010-04-16 2021-01-28 Biogen Ma Inc VLA-4 ellenes antitestek
US10040855B2 (en) 2011-05-02 2018-08-07 Millennium Pharmaceuticals, Inc. Formulation for anti-α4β7 antibody
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
JP6345123B2 (ja) 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
US20190225694A1 (en) 2016-06-28 2019-07-25 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
US20190374639A1 (en) 2016-11-21 2019-12-12 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
EP4659808A3 (fr) * 2017-02-17 2026-03-11 Sanofi Molécules de liaison multispécifiques ayant une spécificité pour le dystroglycane et la laminine-2
US12043845B2 (en) 2017-06-08 2024-07-23 Polpharma Biologics S.A. Methods of cell culture
KR102848349B1 (ko) 2018-06-04 2025-08-21 바이오젠 엠에이 인코포레이티드 감소된 효과기 기능을 갖는 항-ｖｌａ-4 항체
WO2022162164A1 (fr) 2021-01-29 2022-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Procedes d'évaluation du risque de développement d'une leuco-entéphalopathie multifocale progressive chez les patients traités par des antagonistes de la vla-4

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL95501A (en) * 1989-09-01 1997-04-15 Hutchinson Fred Cancer Res Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
ES2103468T3 (es) * 1992-02-12 1997-09-16 Biogen Inc Tratamiento de la inflamacion intestinal.
CA2153692C (fr) * 1993-01-12 2011-11-08 Roy R. Lobb Molecules anticorps anti-vla4 recombinantes
AUPP647298A0 (en) 1998-10-13 1998-11-05 Keystone Retaining Wall Systems, Inc. Retaining wall block

Also Published As

Publication number Publication date
NO963097D0 (no) 1996-07-24
JP2013173738A (ja) 2013-09-05
EP0804237A1 (fr) 1997-11-05
EP1759709B1 (fr) 2013-02-27
WO1995019790A1 (fr) 1995-07-27
FR06C0024I1 (fr) 2006-10-13
DK1759709T3 (da) 2013-06-10
PL181827B1 (pl) 2001-09-28
JP2009235078A (ja) 2009-10-15
EP1759709A1 (fr) 2007-03-07
EP0804237B8 (fr) 2006-11-08
ES2270425T3 (es) 2007-04-01
HU9602019D0 (en) 1996-09-30
AU703152B2 (en) 1999-03-18
NZ279730A (en) 1998-04-27
EP0804237B1 (fr) 2006-07-26
JP4115517B2 (ja) 2008-07-09
DK0804237T3 (da) 2006-10-16
DE69535133D1 (de) 2006-09-07
DE122006000043I1 (de) 2007-02-15
NO2017040I1 (no) 2017-08-01
HU220799B1 (hu) 2002-05-28
FR06C0024I2 (fr) 2009-01-02
CN1211123C (zh) 2005-07-20
JPH09508272A (ja) 1997-08-26
CA2182013A1 (fr) 1995-07-27
KR100367948B1 (ko) 2003-07-12
DE69535133T2 (de) 2008-08-21
NL300238I2 (nl) 2007-05-01
PT804237E (pt) 2006-10-31
JP2013165718A (ja) 2013-08-29
EP0804237A4 (fr) 2003-04-16
CN1140413A (zh) 1997-01-15
NO319867B1 (no) 2005-09-26
PL315634A1 (en) 1996-11-25
HUT75129A (en) 1997-04-28
NO963097L (no) 1996-09-24
NO2017040I2 (no) 2018-08-28
FI962958L (fi) 1996-09-24
NO2006008I2 (no) 2009-06-15
CA2182013C (fr) 2007-07-17
MX9602971A (es) 1998-01-31
ES2424292T3 (es) 2013-09-30
NO2006008I1 (no) 2006-08-07
FI117509B (fi) 2006-11-15
FI962958A0 (fi) 1996-07-24
JP5487382B2 (ja) 2014-05-07
NL300238I1 (fr) 2006-10-02
KR970700513A (ko) 1997-02-12
JP2006045237A (ja) 2006-02-16
ATE333895T1 (de) 2006-08-15
AU1696095A (en) 1995-08-08

Similar Documents

Publication Publication Date Title
LU91271I2 (fr) Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
LU92912I2 (fr) Mépolizumab et ses dérivés pharmaceutiquement acceptables (nucala)
ES2191292T3 (es) Compuestos antivirales poliaromaticos.
UA48940C2 (uk) Рекомбінатні il4 антитіла, які використовуються для лікування il4-опосередкованих порушень
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
MY154009A (en) Anti-alpha v beta 6 antibodies
PT723538E (pt) Compostos triciclicos de carbamato uteis para a ainibicao da funcao da proteina g e para o tratamento de doencas proliferativas
ATE256671T1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)- piperazin-derivate
AP9200410A0 (en) Retroviral protease inhibitors.
DE69831409D1 (de) Chalcon-derivate mit antiproliferativer aktivität
ATE199321T1 (de) Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen.
DE69710111D1 (de) Behandlung und Prophylaxe von Pankreatitis
DE69736180D1 (de) Behandlung von manischen erkrankungen
ATE247955T1 (de) Selenophen-antitumormittel
DK1152760T3 (da) Anvendelse af 4-aminopyridin til behandling af perifere neuropatier
DK0517787T3 (da) Fremgangsmåde til behandling af terapiresistent skizofreni med amperozide
GR1001309B (el) Μεθοδος παρασκευης παραγωγου ενωσεως της διχλωροανιλινης.
FR2721314B1 (fr) Dérivés de pyrrolidine, leur préparation et les médicaments les contenant.
BR9611520A (pt) Composto hemo-reguladores.
MX9704739A (es) Monomeros de 3,3-(disustituido)ciclohexan-1-ona y compuestos relacionados.